Environmental

Keros Therapeutics’ R&D intensity is high versus typical biotech peers, supporting a lower-carbon, knowledge-based operating model with limited direct manufacturing emissions exposure.

The company’s asset-light profile likely reduces Scope 1 and 2 footprint relative to peers with internalized production, though supply-chain and clinical-trial impacts still remain material.

No disclosed environmental controversy or heavy industrial footprint is provided, which compares favorably with peers facing larger permitting, waste, or emissions-management burdens.

Environmental disclosure remains limited in the supplied data, so peer-relative strength appears driven more by business model than by evidenced emissions or resource-management leadership.

Social

High R&D spending relative to revenue indicates sustained investment in scientific talent and patient-focused innovation, which is generally stronger than peers with thinner development pipelines.

The company’s research model can support workforce quality and specialized employment, while also concentrating social risk in clinical execution and trial ethics similar to other biotech peers.

Stock-based compensation is moderate relative to revenue, suggesting less severe dilution pressure on employees than peers with more aggressive equity-based pay structures.

No material labor, product-safety, or access-to-medicine controversy is provided, leaving Keros positioned as broadly in line to somewhat better than peers on social risk.

Governance

Debt-to-equity is very low, which reduces creditor pressure and can support governance flexibility relative to more levered peers.

Stock-based compensation at 1.52% of revenue is manageable, but it still signals ongoing dilution risk that is common in biotech and can weigh on alignment versus peers.

The provided metrics do not show severe balance-sheet stress, yet net debt to EBITDA remains meaningful, so capital discipline appears adequate rather than clearly superior.

No board, audit, or shareholder-rights data is supplied, limiting evidence of governance strength and keeping the relative assessment below top-tier peers.

Overall Score

Keros Therapeutics screens as stronger than many biotech peers overall, led by an asset-light, R&D-driven operating model with limited direct environmental burden.

Score Driver: High R&D Intensity With Limited Direct Environmental Exposure Relative To Peers